Fox BIOSYSTEMS announces today that they successfully closed on their funding round, raising €5.8M in new capital. Investors in this round are Heran Partners, LRM, The Gemma Frisius Fund, KU Leuven, and NetScientific.
FOX BIOSYSTEMS has developed an innovative Surface Plasmon Resonance (SPR) technology using optical sensors. Their product, the White FOx, combines a microfluidics- free dip-in protocol for fast and user friendly SPR sensing. The unique approach of the White FOx eliminates the risk of clogging and cross-contamination when using complex samples such as lysates, whole blood or large particles. The sensor probes are available with several generic surface chemistries and can be switched easily to allow the detection of different target molecules, including antibodies, nanobodies, microvesicles, phages and large particles, all with a single lab device.
A wide range of applications make the White FOx the ideal option for any life science or biopharmaceutical research lab. Kinetic affinity analysis, label free biomolecule quantification and fast specific and ultra-sensitive sandwich assays are all possible and uniquely facilitate analysis of complex unpurified samples.
The additional raised capital will be used to scale up the company’s operations, accelerate the development of new application areas, and to boost the commercialization of this unique system.
Thomas van Elzakker, CEO of FOx BIOSYSTEMS: “We are very happy with the strong support of our investors for our highly motivated team in realizing our vision for FOx BIOSYSTEMS. They are confidently investing in our fast commercial growth today, while also enabling us to deliver on our exciting innovation roadmap for tomorrow. The White FOx system offers a solution to many of today’s analysis challenges, and it will continue to be key in revealing new data and helping scientists to reach their goals more quickly.”
Katleen Vandersmissen, PhD, Chair of FOx BIOSYSTEMS and Managing Partner of HERAN Partners: “With HERAN we try to spot those technologies and teams that can make a difference and positive impact within the domain of Life Sciences. We believe that FOx, now strongly backed by this financing round and the recent EIC grant, is up for success based on their innovative take and ease of use on complex samples.”